Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide
Conditions
Interventions
Melflufen
Pomalidomide
+1 more
Locations
105
United States
US17
Tucson, Arizona, United States
US01
Fresno, California, United States
US11
Gainesville, Florida, United States
US12
Orange City, Florida, United States
US-19
Plantation, Florida, United States
US16
Boise, Idaho, United States
Start Date
June 12, 2017
Primary Completion Date
February 3, 2021
Completion Date
February 3, 2023
Last Updated
January 30, 2024
NCT06679101
NCT05969860
NCT06870760
NCT06383143
NCT06057402
NCT07523555
Lead Sponsor
Oncopeptides AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions